TR199901730T2 - �ift halkal� karboksamidler ve bunlar�n terap�tik kullan�m� - Google Patents

�ift halkal� karboksamidler ve bunlar�n terap�tik kullan�m�

Info

Publication number
TR199901730T2
TR199901730T2 TR1999/01730T TR9901730T TR199901730T2 TR 199901730 T2 TR199901730 T2 TR 199901730T2 TR 1999/01730 T TR1999/01730 T TR 1999/01730T TR 9901730 T TR9901730 T TR 9901730T TR 199901730 T2 TR199901730 T2 TR 199901730T2
Authority
TR
Turkey
Prior art keywords
kullan
karboksamidler
halkal
bunlar
terap
Prior art date
Application number
TR1999/01730T
Other languages
English (en)
Turkish (tr)
Inventor
Joan Dyke Hazel
Gary Montana John
Original Assignee
Darwin Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623860.5A external-priority patent/GB9623860D0/en
Priority claimed from GBGB9708062.6A external-priority patent/GB9708062D0/en
Application filed by Darwin Discovery Limited filed Critical Darwin Discovery Limited
Publication of TR199901730T2 publication Critical patent/TR199901730T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR1999/01730T 1996-11-15 1997-11-17 �ift halkal� karboksamidler ve bunlar�n terap�tik kullan�m� TR199901730T2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623860.5A GB9623860D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9708062.6A GB9708062D0 (en) 1997-04-22 1997-04-22 Novel compounds

Publications (1)

Publication Number Publication Date
TR199901730T2 true TR199901730T2 (xx) 1999-09-21

Family

ID=26310411

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01730T TR199901730T2 (xx) 1996-11-15 1997-11-17 �ift halkal� karboksamidler ve bunlar�n terap�tik kullan�m�

Country Status (22)

Country Link
US (2) US6353010B1 (enExample)
EP (1) EP0944616B1 (enExample)
JP (1) JP2001504479A (enExample)
KR (1) KR20000053274A (enExample)
CN (1) CN1114604C (enExample)
AT (1) ATE242234T1 (enExample)
AU (1) AU726590B2 (enExample)
BR (1) BR9713507A (enExample)
CA (1) CA2268037A1 (enExample)
CZ (1) CZ158299A3 (enExample)
DE (1) DE69722656T2 (enExample)
DK (1) DK0944616T3 (enExample)
ES (1) ES2200163T3 (enExample)
HU (1) HUP0000189A3 (enExample)
ID (1) ID21698A (enExample)
IL (1) IL129337A0 (enExample)
NO (1) NO992337L (enExample)
NZ (1) NZ335197A (enExample)
RU (1) RU2176642C2 (enExample)
SK (1) SK283534B6 (enExample)
TR (1) TR199901730T2 (enExample)
WO (1) WO1998022460A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
GB0003256D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
KR20040010713A (ko) * 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
CN1902193B (zh) 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
US20070225308A1 (en) * 2004-03-15 2007-09-27 Kyowa Hakko Kogyo Co.,Ltd. 2-Amino Quinazoline Derivative
AU2006214184B2 (en) * 2005-02-17 2012-02-02 Albany Molecular Research, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのtnf阻害剤の使用
MX2008010645A (es) * 2006-02-20 2008-10-14 Astellas Pharma Inc Derivado de amida o sal del mismo.
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2008019363A2 (en) * 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
NZ575410A (en) * 2006-09-07 2012-03-30 Biogen Idec Inc 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
CA2752885A1 (en) 2009-02-27 2010-09-02 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and methods of use thereof
EP2611789A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
WO2014037340A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CN108440333A (zh) * 2018-03-29 2018-08-24 江苏道博化工有限公司 分散染料中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140442A (enExample) 1974-04-16 1975-11-11
EP0116938A1 (en) 1983-02-14 1984-08-29 Usv Pharmaceutical Corporation Benzoheterocyclic carbamates
DE3835660A1 (de) * 1988-03-25 1989-10-12 Bayer Ag 7-substituierte 2-carbonamido-benzthiazol-3-oxide
DE4014937A1 (de) 1990-05-10 1991-11-14 Bayer Ag 2,3-disubstituierte chinoxaline als leistungsfoerderer fuer tiere
GB9219634D0 (en) 1992-09-16 1992-10-28 Ici Plc Heterocyclic compounds
GB9219632D0 (en) 1992-09-16 1992-10-28 Ici Plc Heterocyclic compounds
AU675680B2 (en) 1992-10-14 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
GB9301660D0 (en) 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
ES2152414T3 (es) * 1994-07-22 2001-02-01 Byk Gulden Lomberg Chem Fab Dihidrobenzofuranos.
US6083961A (en) 1994-08-03 2000-07-04 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds as bradykinin antagonists
AU699489B2 (en) * 1994-10-12 1998-12-03 Euro-Celtique S.A. Novel benzoxazoles
US5665737B1 (en) 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles

Also Published As

Publication number Publication date
NO992337D0 (no) 1999-05-14
NZ335197A (en) 2000-11-24
HUP0000189A3 (en) 2002-01-28
EP0944616B1 (en) 2003-06-04
CN1237168A (zh) 1999-12-01
NO992337L (no) 1999-05-14
SK64499A3 (en) 2000-03-13
KR20000053274A (ko) 2000-08-25
CZ158299A3 (cs) 1999-09-15
JP2001504479A (ja) 2001-04-03
BR9713507A (pt) 2000-02-29
IL129337A0 (en) 2000-02-17
DK0944616T3 (da) 2003-09-29
ATE242234T1 (de) 2003-06-15
HUP0000189A2 (hu) 2001-04-28
AU4960297A (en) 1998-06-10
US6353010B1 (en) 2002-03-05
US20020094987A1 (en) 2002-07-18
EP0944616A1 (en) 1999-09-29
ES2200163T3 (es) 2004-03-01
RU2176642C2 (ru) 2001-12-10
ID21698A (id) 1999-07-15
SK283534B6 (sk) 2003-09-11
DE69722656T2 (de) 2004-05-13
AU726590B2 (en) 2000-11-09
CN1114604C (zh) 2003-07-16
CA2268037A1 (en) 1998-05-28
WO1998022460A1 (en) 1998-05-28
DE69722656D1 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
DE69938038D1 (de) Korrektur von Messungen des Signal-Intereferenz-Verhältnisses
CY1106436T1 (el) Φαινυλοφαινανθριδινες με δραση αναστολης pde - ιv
TR200101126T2 (tr) İkameli fenil türevleri, hazırlanma ve kullanımları
NO933999L (no) Fibrinogenreseptorantagonister
ATE269850T1 (de) 3-thiocarbamoylpyrazol-derivate als pestiziden
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
ATE226201T1 (de) Substituierte pyridylpyrazole
DE60103853D1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE210163T1 (de) Triazinpolymere und deren verwendung in elektrolumineszierenden anordnungen
DE60103375D1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
DK155524C (da) Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
NO20022976L (no) 2-(1H-indol-3yl)-2-okso-acetamider med antitumoraktivitet
TR200400645T4 (tr) İkameli Fenil Piperazin türevleri, Bunların Hazırlanması ve kullanımları
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
TR200001141T2 (tr) Motilin reseptörü antagonistleri olarak yararlı siklopenten türevleri.
NO306116B1 (no) Ny benzotiadiazinforbindelse og farmasöytiske sammensetninger
ATE44381T1 (de) Heterocyclische verbindungen und ihre herstellung und verwendung.
DE60127131D1 (de) Tricyclische imidazopyridine
SE9903290D0 (sv) Novel compounds
DK1206256T3 (da) Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse
DE69940932D1 (de) Orale Zusammensetzungen mit 8-chloro-6,11-dihydro-11-(4-piperidylene)-5H-benzoÄ5,6Ü-cyclo-heptaÄ1,2-bÜpyridin
DE69012619D1 (de) Bis(1-Hydrocarbyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-amin-derivate und stabilisierte Zusammensetzungen.
ATE122663T1 (de) Bis-benzotriazol-verbindungen und damit stabilisierte polymerstoffe.